New drug cocktail aims to stop head and neck cancer return

NCT ID NCT07535567

Not yet recruiting Disease control Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the drug benmelstobart to standard radiotherapy and nimotuzumab can help prevent head and neck cancer from coming back after surgery. About 386 patients with intermediate-risk features will be randomly assigned to one of two groups. The main goal is to see if the combination improves how long patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nimotuzumab and benmelstobart (drugs)
What this could lead to: If successful, this could provide a more effective adjuvant treatment option for head and neck cancer patients with intermediate-risk features, potentially improving disease-free survival.
What could go wrong: This is an early-phase trial (Phase II/III) that hasn't started recruiting yet. Adding another drug may increase side effects without clear benefit, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.